The lawsuit, filed by the Outsourcing Facilities Association , FarmaKeio Custom Compounding and North American Custom Laboratories in the U.S. District Court for the Northern District of Texas, argues ...
Drug compounders aren’t ready to give up their ability to produce off-brand versions of Novo Nordisk’s weight-loss drug ...
Hims & Hers stock drops 26% as FDA resolves semaglutide shortage, threatening GLP-1 revenue. Click here to find out why HIMS ...
The FDA recently removed semaglutide from its drug shortage list, which has not been considered commercially available since ...
A lawsuit challenges the FDA's decision to remove semaglutide from the shortage list, alleging it was arbitrary and harms ...
MarketBeat on MSN15h
Wall Street's Most Wanted: 2 Highly Shorted Stocks Right NowShort-selling is an interesting part of the stock market that can be dangerous and even controversial. Investors selling ...
A group that represents pharmacies that have been producing off-brand versions of GLP-1 weight-loss drugs just filed another ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback